Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.

van Rensburg, Walter J Janse; Roodt, Jan P; Lamprecht, Seb; Meiring, S Muriel; Badenhorst, Philip N

van Rensburg, Walter J Janse; Roodt, Jan P; Lamprecht, Seb; Meiring, S Muriel; Badenhorst, Philip N.

Affiliation

van Rensburg WJ; Preclinical Drug Testing Facility, Department of Haematology and Cell Biology (G2), Faculty of Health Sciences, University of the Free State, PO Box 339, Bloemfontein 9300, South Africa. jansevrwj@ufs.ac.za

Clin Exp Med ; 12(4): 257-63, 2012 Dec.

Article in En | MEDLINE | ID: mdl-22219002

Subject(s)

Antibodies, Monoclonal/administration & dosage; Anticoagulants/administration & dosage; Immunoglobulin Fab Fragments/administration & dosage; Thrombosis/prevention & control; Tyrosine/analogs & derivatives; Abciximab; Animals; Disease Models, Animal; Primates; Tirofiban; Treatment Outcome; Tyrosine/administration & dosage

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thrombosis / Tyrosine / Immunoglobulin Fab Fragments / Antibodies, Monoclonal / Anticoagulants Limits: Animals Language: En Journal: Clin Exp Med Year: 2012 Document type: Article

Fulltext

XML

PubMed Links

Search on Google